ENXTPA:SANPharmaceuticals
How New CHMP Opinions on Dupixent and Acoziborole Will Impact Sanofi (ENXTPA:SAN) Investors
In late February 2026, Sanofi and Regeneron reported that the European Medicines Agency’s CHMP issued positive opinions for Dupixent in young children with chronic spontaneous urticaria and for Acoziborole Winthrop as a single-dose oral treatment for gambiense sleeping sickness, with final EU decisions expected in the months that followed.
These CHMP endorsements highlight how Sanofi’s immunology and neglected tropical disease programs may broaden its treatment footprint across both...